Heterocyclic Compounds

Matches 1,651 - 1,700 out of 9,534	< 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 >

Document	Document Title
WO/2015/191401A1	TRICYCLIC COMPOUNDS AS ALPHA- 7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various di...
WO/2015/185207A1	ALKYL AND ARYL DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN The present invention relates to compounds of general formula (I) having dual pharmacological activity towards both the sigma (σ) receptor, and the μ-opiod receptor and more particularly to diazaspiro undecane compounds having this pha...
WO/2015/184644A1	COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING HEPATITIS C VIRUS, AND USES THEREOF Compounds and pharmaceutical compositions for inhibiting the hepatitis c virus (HCV), and uses thereof, are disclosed. The present invention provides compounds as represented by formula (Ia) or (Ib), stereoisomers thereof, tautomers ther...
WO/2015/184753A1	COMPOUNDS FOR INHIBITING HEPATITIS C VIRUS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF Provided are compounds for inhibiting a hepatitis C virus (HCV), stereisomers, tautomers, isotope isomers, hydrates, esterified or amidated prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions thereof and uses thereof...
WO/2015/181063A1	SUBSTITUTED TETRAHYDROPYRIDOTHIENOPYRIMIDINES The present invention relates to substituted tetrahydropyridothienopyrimidine compounds of general formula(I)as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said com...
WO/2015/182724A1	SUBSTITUTED TROPANE DERIVATIVES Provided are compounds that are useful as prophylactic or therapeutic agents for various diseases involving T-type calcium channels, such as hypertension, arrhythmia, pain and cancer, said compounds having antagonistic activity against T...
WO/2015/180642A1	CERTAIN PROTEIN KINASE INHIBITORS Provided are compound of formula (I) as certain CDK4/6 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
WO/2015/177688A1	FUSED TRIAZOLE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS Compounds of the general formula (I), wherein one of X1 and X2 represents N, and the other one of X1 and X2 represents -C(CH3), A represents unsubstituted or substituted 5-, 6-or 10-membered aryl or heteroaryl, n is 0 or 1 and B is a bic...
WO/2015/173181A1	COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY The present invention provides compounds of formula (I) wherein A, R1, R2 and R3 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compou...
WO/2015/171993A1	CRYSTAL FORMS The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern as shown in one of Figures 1-10.
WO/2015/165279A1	POLYFLUORINATED COMPOUNDS ACTING AS BRUTON'S TYROSINE KINASE INHIBITORS Provided are new polyfluoro-substituted pyrazolopyrimidine compounds or salts represented by formulae (I) to (IX), a preparation method therefor, and a method for using said compounds and a preparation thereof to treat and inhibit autoim...
WO/2015/166370A1	HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS The present invention provides, in part, compounds of Formula (I): and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or s...
WO/2015/167300A1	ORGANIC ELECTROLUMINESCENT COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME The present disclosure relates to an organic electroluminescent compound of Formula 1 (variables R1 -R10 defined herein), and an organic electroluminescent device comprising the same. By using the organic electroluminescent compound acco...
WO/2015/164520A1	SUBSTITUTED 2,4,5,6-TETRAHYDROPYRROLO[3,4-C] PYRAZOLE AND 4,5,6,7-TETRAHYDRO-2H-PYRAZOLO [4,3-C] PYRIDINE COMPOUNDS AS GLYT1 INHIBITORS The invention provides a chemical entity of Formula (I), wherein R1, R2, R3, R4, R5 and X have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range ...
WO/2015/162515A1	HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or sal...
WO/2015/164508A1	SUBSTITUTED [1,2,4] TRIAZOLO [1,5-A] PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS The invention provides a chemical entity of Formula (I): wherein R1, R2, X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of met...
WO/2015/158291A1	BCR-ABL DIPLOID INHIBITOR, PREPARATION METHOD THEREFOR, AND USES THEREOF Disclosed are compounds or pharmaceutically acceptable salts thereof having the following general formula: R-Linker-R. The compounds or pharmaceutically acceptable salts thereof provided by the present invention are used as Bcr-Abl diplo...
WO/2015/158025A1	COMPOUND AND PREPARATION METHOD THEREFOR AND USES THEREOF The present invention provides a compound and a preparation method therefor and uses thereof. The compound is a compound represented by formula I or an enantiomer, a diastereoisomer, a racemate, a pharmaceutically acceptable salt, a crys...
WO/2015/154630A1	ANALOGUES OF 4H-PYRAZOLO[1,5-Α]BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS Disclosed is a series of analogues of 4H-pyrazolo[1,5-α]benzimidazole compound as PARP inhibitors. In particular, disclosed in the invention is a compound as shown by formula (I) or a pharmaceutically acceptable salt thereof as a PARP i...
WO/2015/155549A1	ANTIBACTERIAL COMPOUNDS This invention relates to antibacterial and anti-mycobacterial drug compounds of formula I. It also relates to pharmaceutical formulations of antibacterial drug compounds. It also relates to uses of the derivatives in treating bacterial ...
WO/2015/153683A1	ANTI-FIBROTIC PYRIDINONES This application relates to polycyclic compounds with a pyridinone or pyridinone derivative core including, substituted pyridinones, 5,6- and 6,6- bicyclic heterocycles and substituted pyridine-thiones. This application also discloses me...
WO/2015/152368A1	OXAZOLIDINONE AND OXAZINANONE DERIVATIVES Provided is a novel compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The compound or pharmaceutically acceptable salt thereof exhibits orexin (OX) receptor antagonistic action, and thus is useful for the...
WO/2015/146928A1	HETEROCYCLIC COMPOUND Provided is a compound, or a salt thereof, that has an excellent PKC inhibitory action, and that is useful as a prophylactic or therapeutic agent for immunological diseases, inflammatory diseases, etc. A compound represented by formula (...
WO/2015/148597A1	AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C The present application provides a compound of formula (I) and/or a salt thereof, wherein R1, G, and X are as defined herein. A compound of formula (I) and/or its salts have aPKC inhibitory activity, and may be used to treat proliferativ...
WO/2015/147247A1	TRICYCLIC DERIVATIVE HAVING HIV REPLICATION INHIBITORY ACTIVITY A compound represented by formula (I) or formula (VI), which has antiviral activity, especially HIV replication inhibitory activity; and a pharmaceutical product which contains this compound. (In the formulae, ring A represents a substit...
WO/2015/147129A1	ORGANIC TRANSISTOR, COMPOUND, ORGANIC SEMICONDUCTOR MATERIAL FOR NON-LIGHT-EMITTING ORGANIC SEMICONDUCTOR DEVICE, MATERIAL FOR ORGANIC TRANSISTOR, COATING LIQUID FOR NON-LIGHT-EMITTING ORGANIC SEMICONDUCTOR DEVICE, METHOD FOR MANUFACTURING ORGANIC TRANSISTOR, METHOD FOR MANUFACTURING ORGANIC SEMICONDUCTOR FILM, ORGANIC SEMICONDUCTOR FILM FOR NON-LIGHT-EMITTING ORGANIC SEMICONDUCTOR DEVICE, AND METHOD FOR SYNTHESIZING ORGANIC SEMICONDUCTOR MATERIAL An organic transistor that has a semiconductor active layer containing a compound that can be represented by formula (1) and has a molecular weight of 3,000 or less exhibits high carrier mobility (X represents an oxygen, sulfur, selenium...
WO/2015/146455A1	ORGANIC-ELECTROLUMINESCENT-ELEMENT MATERIAL AND ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME This invention discloses an organic electroluminescent element that exhibits improved luminous efficacy, ensures sufficient driving stability, and has a simple structure. This invention also discloses a material used in said organic elec...
WO/2015/146929A1	HETEROCYCLIC COMPOUND Provided is a compound, or a salt thereof, that has an excellent PKC inhibitory action, and that is useful as a prophylactic or therapeutic agent for immunological diseases, inflammatory diseases, etc. A compound represented by formula (...
WO/2015/140559A1	MUSCARINIC RECEPTOR AGONISTS This invention relates to compounds that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds...
WO/2015/131856A1	HETEROCYCLIC COMPOUNDS, AND PREPARATION METHOD AND USE THEREOF Provided are heterocyclic compounds represented by formula (I), stereoisomers or pharmaceutically acceptable salts of said compounds, a pharmaceutical composition of said compounds, and an application of said compounds in the preparation...
WO/2015/130915A1	DIKETOPYRROLOPYRROLE SEMICONDUCTING MATERIALS, PROCESSES FOR THEIR PREPARATION AND USES THEREOF Described herein are heterocyclic organic compounds. More specifically, described herein are compounds based on the combination of fused pyrrole structures with diketopyrrolopyrrole structures, methods for making these compounds, and use...
WO/2015/128676A1	N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2,8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS The present invention relates to compounds of formula (I) wherein R1, R2, R3 and R4 are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1 –also kno...
WO/2015/125820A1	BIOTIN VARIANT, STREPTAVIDIN MUTANT, AND USES THEREOF The problem addressed by the present invention is: to provide a streptavidin mutant having a reduced affinity to natural biotin; and furthermore to provide a biotin variant that has a high affinity to the streptavidin mutant having reduc...
WO/2015/124544A1	3-(PYRIMIDINE-2-YL)IMIDAZO[1,2-A]PYRIDINES The application relates to novel 3-(pyrimidine-2-yl) imidazo[1,2-a]pyridines of formula (I), methods for producing same, the use thereof alone or in combinations for treating and/or preventing diseases, and the use thereof for producing ...
WO/2015/120737A1	SUBSTITUTED PYRIDOPYRIMIDINE COMPOUNDS, PREPARATION METHODS THEREFOR AND USES THEREOF Disclosed are substituted pyridopyrimidine compounds, preparation methods therefor and uses thereof. The general structure of the substituted pyridopyrimidine compounds is represented by formula I, wherein Ar is substituted pyridyl. The ...
WO/2015/119712A1	TETRACYCLIC CDK9 KINASE INHIBITORS Disclosed are compounds of Formula (Ia), and pharmaceutically acceptable salts thereof, Formula (Ia), wherein X, Y, R1, R2, R3A, R3B, and R4 are as described herein. The compounds may be used as agents in the treatment of diseases, inclu...
WO/2015/118097A1	HEXAHYDROFUROPYRROLES AS PDE1 INHIBITORS The present invention provides hexahydrofuropyrroles as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
WO/2015/115116A1	ORGANIC LIGHT EMITTING ELEMENT Provided is an organic light emitting element which exhibits stable performance in the atmosphere. This organic light emitting element comprises a positive electrode, a negative electrode and a first organic compound layer that is arrang...
WO/2015/115673A1	FUSED IMIDAZOLE COMPOUNDS The present invention provides compounds represented by formula (I), pharmaceutically acceptable salts thereof, N-oxides thereof, solvates thereof or prodrugs thereof (wherein the characters are as defined in the description). The compou...
WO/2015/106624A1	2,4(1H,3H)-PYRIMIDINEDIONE DERIVATIVES AND PREPARATION METHOD THEREFOR The present invention relates to 3,7-dihydro-1,3,7-trimethyl-1H-imidazo[4,5-d]pyrimidine-2,6- dione, 1,7-dihydro-6H-imidazo[4,5-d]pyrimidine-6-one and 2,4(1H,3H)-pyrimidinedione derivatives, and preparation method therefor.
WO/2015/106012A1	AZAINDOLE DERIVATIVES Disclosed are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are defined in the specification. This disclosure also relates to materials and methods for prepar...
WO/2015/104254A1	AMIDO-SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE AND/OR ANGIOGENESIS DISORDERS The present invention relates to amido-substituted imidazopyridazine compounds of general formula (I): in which A, E, R2, R3, R4 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful...
WO/2014/052699A9	AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C The present invention provides a compound of formula (I) or a salt thereof, wherein R7, R8, R9, G, and X are as defined herein. A compound of formula (I) and its salts have a PKC inhibitory activity, and may be used to treat proliferativ...
WO/2015/101265A1	1-(3-AMINOPROPYL) SUBSTITUTED CYCLIC AMINE COMPOUNDS, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF Provided are 1-(3-aminopropyl) substituted cyclic amine compounds as represented by formula (I), pharmaceutically acceptable salts, enantiomers, diastereoisomers, racemates and mixtures thereof, and a method of synthesizing said 1-(3-ami...
WO/2015/100420A1	CORTISTATIN ANALOGUES AND SYNTHESES AND USES THEREOF Provided herein are compounds of Formula (A), (B), (C), (D) and (E), pharmaceutically acceptable salts, quaternary amine salts, and N-oxides thereof, and pharmaceutical compositions thereof. Compounds of Formula (A), (B), (C), (D), and (...
WO/2015/092431A1	PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS The present invention relates to compounds that are useful as inhibitors of the activity of Wee-1 kinase. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compound...
WO/2015/092592A1	NOVEL 3,4-DISUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINES AND 4,5-DISUBSTITUTED-7H-PYRROLO[2,3-C]PYRIDAZINES AS LRRK2 INHIBITORS The present invention provides novel 3,4-disubstituted-1 H-pyrrolo[2,3- Jb]pyridine derivatives and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazine derivatives of Formula (I), and the pharmaceutically acceptable salts thereof (I) wherein R...
WO/2015/087995A1	CYCLOALKYL OR HETEROCYCLYL PYRAZOLOPYRIDINE DERIVATIVE A compound which has excellent LCAT activation effects, is useful as an active ingredient of a therapeutic or preventive agent for arteriosclerosis, arteriosclerotic cardiovascular disease, coronary heart disease (including heart failure...
WO/2015/086526A1	FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY A series of fused tricyclic imidazole derivatives, in particular dihydro-1H-cyclopenta[4,5]imidazo[1,2-a]pyridine derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the trea...
WO/2015/086506A1	FUSED IMIDAZOLE AND PYRAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY A series of substituted benzimidazole, imidazo[1,2-a]pyridine and pyrazolo[1,5-a]pyridine derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention ...

Matches 1,651 - 1,700 out of 9,534	< 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 >